Physician profile
Gary L Poling
NPI 1487730941
$860.31
in general payments reported to CMS, 2019-2025
11 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67.11 · 2020: $67.00 · 2021: $93.24 · 2022: $154 · 2023: $238 · 2024: $107 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $479.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $478.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.93 | 2022-2025 | |
| Amgen INC. | $207.03 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $79.17 | 2019-2023 | |
| Novo Nordisk INC | $58.55 | 2023-2025 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $58.07 | 2021-2022 | |
| Glaxosmithkline, LLC. | $40.03 | 2020 | |
| Sunovion Pharmaceuticals INC. | $39.09 | 2019 | |
| Shield Therapeutics INC | $22.71 | 2024 | |
| Lilly USA, LLC | $16.90 | 2021 | |
| Echosens North America, INC. | $13.79 | 2023 | Fibroscan |
| Medtronic Vascular, INC. | $13.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Poling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.